JP2012532094A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012532094A5 JP2012532094A5 JP2012516964A JP2012516964A JP2012532094A5 JP 2012532094 A5 JP2012532094 A5 JP 2012532094A5 JP 2012516964 A JP2012516964 A JP 2012516964A JP 2012516964 A JP2012516964 A JP 2012516964A JP 2012532094 A5 JP2012532094 A5 JP 2012532094A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- protofibril
- oligomer
- terminal truncated
- alzheimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229960005486 vaccine Drugs 0.000 claims 6
- 239000000178 monomer Substances 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 230000024203 complement activation Effects 0.000 claims 1
- 230000009260 cross reactivity Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22110509P | 2009-06-29 | 2009-06-29 | |
| US61/221,105 | 2009-06-29 | ||
| PCT/IB2010/052947 WO2011001366A1 (en) | 2009-06-29 | 2010-06-29 | N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017083057A Division JP6884025B2 (ja) | 2009-06-29 | 2017-04-19 | アルツハイマ病の治療および診断方法における使用のためのＮ末端切断型アミロイドβプロトフィブリル／オリゴマ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012532094A JP2012532094A (ja) | 2012-12-13 |
| JP2012532094A5 true JP2012532094A5 (https=) | 2013-08-08 |
Family
ID=42832352
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012516964A Withdrawn JP2012532094A (ja) | 2009-06-29 | 2010-06-29 | アルツハイマ病の治療および診断方法における使用のためのＮ末端切断型アミロイドβプロトフィブリル／オリゴマ |
| JP2017083057A Active JP6884025B2 (ja) | 2009-06-29 | 2017-04-19 | アルツハイマ病の治療および診断方法における使用のためのＮ末端切断型アミロイドβプロトフィブリル／オリゴマ |
| JP2019142344A Pending JP2019218362A (ja) | 2009-06-29 | 2019-08-01 | アルツハイマ病の治療および診断方法における使用のためのＮ末端切断型アミロイドβプロトフィブリル／オリゴマ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017083057A Active JP6884025B2 (ja) | 2009-06-29 | 2017-04-19 | アルツハイマ病の治療および診断方法における使用のためのＮ末端切断型アミロイドβプロトフィブリル／オリゴマ |
| JP2019142344A Pending JP2019218362A (ja) | 2009-06-29 | 2019-08-01 | アルツハイマ病の治療および診断方法における使用のためのＮ末端切断型アミロイドβプロトフィブリル／オリゴマ |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20120100129A1 (https=) |
| EP (2) | EP2448968B1 (https=) |
| JP (3) | JP2012532094A (https=) |
| AU (1) | AU2010267640B2 (https=) |
| CA (1) | CA2765602C (https=) |
| CY (1) | CY1124034T1 (https=) |
| DK (1) | DK2448968T3 (https=) |
| ES (1) | ES2864049T3 (https=) |
| HR (1) | HRP20210611T1 (https=) |
| HU (1) | HUE053949T2 (https=) |
| LT (1) | LT2448968T (https=) |
| PL (1) | PL2448968T3 (https=) |
| PT (1) | PT2448968T (https=) |
| SI (1) | SI2448968T1 (https=) |
| SM (1) | SMT202100237T1 (https=) |
| WO (1) | WO2011001366A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| RU2429244C2 (ru) | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| CA2828433C (en) | 2011-03-16 | 2020-08-04 | Probiodrug Ag | Diagnostic antibody assay |
| WO2016005466A2 (en) | 2014-07-10 | 2016-01-14 | Bioarctic Neuroscience Ab | IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES |
| WO2017013599A1 (en) | 2015-07-21 | 2017-01-26 | Bioarctic Neuroscience Ab | Method for treatment of traumatic brain injury targeting aggregated peptides |
| BR112019000098A2 (pt) | 2016-07-14 | 2019-04-09 | Bioarctic Ab | proteína de fornecimento ao cérebro, método de tratamento e/ou profilaxia de distúrbios cerebrais em mamíferos que possuem ou encontram-se em risco de desenvolver o mencionado distúrbio e método de diagnóstico e/ou detecção de distúrbios cerebrais em mamíferos suspeitos de possuir ou que se encontram em risco de desenvolver o mencionado distúrbio |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| US20210324056A1 (en) | 2018-07-24 | 2021-10-21 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| JPWO2021006212A1 (https=) * | 2019-07-08 | 2021-01-14 | ||
| US12352719B2 (en) | 2019-09-20 | 2025-07-08 | KYCERA AVX Components Corporation | Somatic cell-based electrical biosensor |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| DK4172199T3 (da) | 2020-06-26 | 2025-08-18 | Bioarctic Ab | Alfa-synuklein-protofibril-bindende antistoffer |
| AU2022307687A1 (en) | 2021-07-09 | 2024-01-04 | Eisai R&D Management Co., Ltd. | Biomarkers for alzheimer's disease treatment |
| US20240352109A1 (en) | 2021-08-30 | 2024-10-24 | Eisai R&D Management Co., Ltd. | Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof |
| AU2022439338A1 (en) | 2022-02-02 | 2024-08-15 | Eisai R&D Management Co., Ltd. | Methods of treatment using p-tau181 level |
| PE20252307A1 (es) | 2022-12-22 | 2025-09-22 | Bioarctic Ab | Anticuerpo que se une a abetape3 |
| WO2025262228A1 (en) | 2024-06-20 | 2025-12-26 | Bioarctic Ab | Bispecific binding molecule |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| DE60043165D1 (de) * | 1999-08-04 | 2009-11-26 | Univ Southern California | Globularer Aufbau vom Amyloid-beta- protein und deren Verwendungen |
| CA2414772C (en) * | 2000-07-07 | 2011-06-28 | Jan Naslund | Prevention and treatment of alzheimer's disease |
| US7122374B1 (en) * | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| WO2004013172A2 (en) * | 2002-07-24 | 2004-02-12 | Innogenetics N.V. | Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
| PT1737891E (pt) * | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
| GB0413726D0 (en) * | 2004-06-18 | 2004-07-21 | Lauras As | Compounds |
| SE0401601D0 (sv) * | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| MX2007000998A (es) * | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| RU2429244C2 (ru) * | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| EP2207568B1 (en) * | 2007-11-16 | 2017-05-31 | The Rockefeller University | Antibodies specific for the protofibril form of beta-amyloid protein |
| PT2282758T (pt) * | 2008-04-29 | 2019-02-12 | Bioarctic Ab | Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína |
-
2010
- 2010-06-29 LT LTEP10739701.0T patent/LT2448968T/lt unknown
- 2010-06-29 EP EP10739701.0A patent/EP2448968B1/en active Active
- 2010-06-29 HR HRP20210611TT patent/HRP20210611T1/hr unknown
- 2010-06-29 ES ES10739701T patent/ES2864049T3/es active Active
- 2010-06-29 DK DK10739701.0T patent/DK2448968T3/da active
- 2010-06-29 US US13/379,523 patent/US20120100129A1/en not_active Abandoned
- 2010-06-29 PT PT107397010T patent/PT2448968T/pt unknown
- 2010-06-29 EP EP21153326.0A patent/EP3892633A1/en active Pending
- 2010-06-29 HU HUE10739701A patent/HUE053949T2/hu unknown
- 2010-06-29 WO PCT/IB2010/052947 patent/WO2011001366A1/en not_active Ceased
- 2010-06-29 PL PL10739701T patent/PL2448968T3/pl unknown
- 2010-06-29 JP JP2012516964A patent/JP2012532094A/ja not_active Withdrawn
- 2010-06-29 CA CA2765602A patent/CA2765602C/en active Active
- 2010-06-29 AU AU2010267640A patent/AU2010267640B2/en active Active
- 2010-06-29 SI SI201032068T patent/SI2448968T1/sl unknown
- 2010-06-29 SM SM20210237T patent/SMT202100237T1/it unknown
-
2017
- 2017-04-19 JP JP2017083057A patent/JP6884025B2/ja active Active
-
2019
- 2019-08-01 JP JP2019142344A patent/JP2019218362A/ja active Pending
-
2021
- 2021-04-27 CY CY20211100361T patent/CY1124034T1/el unknown
-
2022
- 2022-12-15 US US18/066,998 patent/US20230295283A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012532094A5 (https=) | ||
| ES2973425T3 (es) | Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del síndrome respiratorio agudo grave (sars-cov-2) | |
| AU2018200886B2 (en) | Compositions and methods for treating and preventing Staphylococcus aureus infections | |
| JP2022031635A5 (https=) | ||
| RU2010120879A (ru) | Антитела против g-белка распираторно-синцитиального вируса (rsv) | |
| NZ596409A (en) | Anti macrophage migration inhibitory factor antibodies | |
| UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
| RU2015126533A (ru) | Анти-cd47 антитела и способы их применения | |
| JP2015523962A5 (https=) | ||
| JP2013524774A5 (https=) | ||
| JP2013506428A5 (https=) | ||
| JP2018529635A5 (https=) | ||
| JP2016533335A5 (https=) | ||
| RU2012139181A (ru) | Стабильная композиция, содержащая антитело | |
| RU2014148502A (ru) | Человеческие антитела к fel d1 и способы их применения | |
| JP2015503909A5 (https=) | ||
| SI2542257T1 (en) | Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI) | |
| RU2016107814A (ru) | Новое антитело к tslp-рецептору человека | |
| TW201927337A (zh) | 一種ｌａｇ－３抗體醫藥組成物及其用途 | |
| CN114729033A (zh) | 抗α-溶血素的抗体及其应用 | |
| RU2017144629A (ru) | Тромбин-связывающие молекулы антител и их применение | |
| IN2014CN04823A (https=) | ||
| RU2013101769A (ru) | Высокоаффинные антитела человека к белку gb цитомегаловирусу (смv) человека | |
| Robinette et al. | Alterations in immunodominance of Streptococcus mutans AgI/II: lessons learned from immunomodulatory antibodies | |
| US12612450B2 (en) | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |